• 06-Apr-2018

    Dr James Garner speaks with CommSec re our GDC-0084 Phase II trial start.
  • 29-Mar-2018

    NDF Research Senior Analyst Stuart Roberts interviews Kazia Therapeutics CEO Dr James Garner as the GDC-0084 phase II trial launches in the US.
  • 30-Nov-2017

    CommSec interview re our new name, Kazia Therapeutics and our clinical trial progress.
  • 04-Jul-2017

    CommSec Executive Series interviews CEO Dr James Garner on benefits of new business model for patients
  • 19-May-2017

    ASX CEO Session interview with FNN
  • 1-May-2017

    Dr James Garner, CEO, speaks to Canary Networks investment forum
  • 19-Apr-2017

    Briefing on ATM program by our CEO, Dr James Garner to the Hon Paul Fletcher MP, Minister for Bradfield
  • 2-Nov-2016

    Dr James Garner discusses in-licencing of GDC-0084 with FNN